Targeted detection of common null alleles


  • Type III CRISPR-Cas technology
  • Simple & fast protocol
  • Available as prototype


GenDx, in collaboration with Scope Biosciences, is proud to introduce CRISPRgo HLA assays. These assays utilize Type III CRISPR-Cas technology for the targeted detection of common null alleles. The detection of these alleles is critically important for transplantation because it directly impacts the compatibility between the donor and recipient in organ and tissue transplantation.

CRISPRgo HLA assays are currently available as prototype.

You have questions or want to arrange a demo?

Contact our Sales Team


See specifications


Distinguishing common HLA null alleles is required and commonplace in HLA typing. ASHI standards requires detection of at least HLA-A*24:09N, -B*51:11N, -C*04:09N, -DRB4*01:03N, -DRB5*01:08N. These null alleles are a result of different molecular modifications including nucleotide substitution, homopolymer extension, homopolymer shortening or indels. GenDx, in collaboration with Scope Biosciences B.V. (Wageningen, the Netherlands) developed a CRISPR-Cas based assay to detect null alleles in a human gDNA sample. The method combines an isothermal LAMP reaction with CRISPR-Cas recognition of a specific target sequence, which is targeted per developed assay, and a fluorescent reporter assay in a single tube. After adding DNA to the assay tube, the reaction is incubated and fluorescent signal is monitored every minute.

A Simple Protocol for Complex Analysis

One of the key highlights of CRISPRgo HLA assays is its remarkably simple protocol. The technology leverages ScopeDx’s expertise in CRISPR-Cas-based assays to create a user-friendly method for identifying null alleles.

How it works:

  1. Sample Preparation: Begin by adding just 1.5ng of genomic DNA to the assay tube.
  2. Incubation: Place the assay tube in a controlled environment, maintaining a temperature of 65°C for 60 minutes.
  3. Real-Time Monitoring: Throughout the incubation period, the system continuously monitors the fluorescent signal, providing real-time data.
  4. Presence or Absence: At the end of the incubation period, CRISPRgo HLA assays deliver a conclusive result, confirming the presence or absence of null alleles in the sample.

Now available as prototype:






CRISPRgo Housekeeping gene



Contact us at for more information.


Log in to browse the downloads.